Biotech Values

[mcbio]

Timely article smile! I am back in MACK and AVEO, added ARIA significantly, also started SGYP due to major weakness from all four of them recently. MACK will have data points from several ph2 and ph3 trials in next 6-8 months.

I see MACK is back down to earth a bit so I will take a closer look here. After quick look at a recent presentation, I see that the pivotal trial for their lead drug appears set to read out in 2H this year. How concerned are you about the potential for failure with this trial? I can respect that MACK has a very deep pipeline but curious about your confidence in the read-out from the pivotal trial of the lead drug later this year. I'll likely sit this one out and view it as a potential play if lead drug fails and there is good amount of weakness afterwards.